At a glance
ClinicalIndex Comparison RecordN/ACompleted· 15 enrolled
Drug / intervention
F-18 fluciclovine-PET/CT scanother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of F-18 Fluciclovine-PET/CT as A Diagnostic Tool for Bone Metastases in Patients With Hormonal Sensitive and Resistant Prostate Adenocarcinoma
In Brief
A clinical study evaluating F-18 fluciclovine-PET/CT scan for Prostate Adenocarcinoma. Completed, enrolled 15 participants across 1 site.
Detailed Summary
Determine diagnostic accuracy of Axumin-PET positive bone lesion by confirmatory bone biopsy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Adenocarcinoma
CountriesUnited States
CollaboratorsBlue Earth Diagnostics, Banner University Medical Center
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartApr 2018
Primary CompletionApr 2021
TodayJul 2026
First PostedApr 12, 2018
Enrollment StartApr 15, 2018
Primary CompletionApr 27, 2021
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 8.2 years ago
Interventions
F-18 fluciclovine-PET/CT scanother
PET/CT imaging with F-18 fluciclovine